Loading…
Trident Lifeline (BSE 543616)₹424.35+2.56%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Trident Lifeline reported sales of ₹47.19 Cr, up 50.4% from Sep 2025, and net profit of ₹6.58 Cr, up 29.5% year on year. For the year to Mar 2026, sales were ₹129 Cr and net profit ₹18.93 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.10 | 19.17 | 13.16 | 15.47 | 11.86 | 34.07 | 23.65 | 31.38 | 25.75 | 50.00 | 33.77 | 47.19 |
| Expenses | 5.64 | 16.72 | 10.63 | 11.37 | 7.74 | 25.39 | 18.39 | 24.42 | 20.56 | 38.85 | 25.12 | 35.65 |
| Operating Profit | 1.42 | 2.35 | 2.48 | 4.04 | 4.06 | 8.53 | 5.16 | 6.85 | 5.08 | 10.98 | 8.51 | 11.32 |
| OPM % | 20.1% | 12.3% | 18.9% | 26.2% | 34.4% | 25.1% | 21.9% | 21.9% | 19.8% | 22.0% | 25.2% | 24.1% |
| Other Income | 0.26 | 1.48 | 1.16 | 0.55 | 0.57 | 1.88 | 1.36 | 1.68 | 4.64 | 1.63 | 0.58 | 0.98 |
| Interest | 0.16 | 0.38 | 0.50 | 0.51 | 0.56 | 1.56 | 1.14 | 1.00 | 1.25 | 0.78 | 0.87 | 1.94 |
| Depreciation | 0.18 | 0.38 | 0.53 | 0.15 | 0.60 | 2.73 | 1.45 | 0.90 | 2.45 | 1.22 | 1.61 | 1.55 |
| Profit before tax | 1.35 | 3.08 | 2.62 | 3.94 | 3.48 | 6.14 | 3.94 | 6.65 | 6.04 | 10.64 | 6.63 | 8.84 |
| Tax % | 21.7% | 46.9% | 38.8% | 28.6% | 26.5% | −0.3% | 29.3% | 23.3% | 22.8% | 36.0% | 23.3% | 25.1% |
| Net Profit | 1.04 | 1.62 | 1.59 | 2.79 | 2.55 | 6.11 | 2.77 | 5.08 | 4.63 | 6.77 | 5.05 | 6.58 |
| EPS (Rs) | 0.95 | 1.78 | 2.00 | 2.70 | 2.44 | 6.16 | 2.67 | 4.28 | 3.61 | 5.65 | 4.23 | 5.53 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 22.06 | 32.03 | 45.10 | 87.16 | 129 | 157 |
| Expenses | 18.97 | 24.93 | 35.89 | 71.76 | 101 | 120 |
| Operating Profit | 2.99 | 5.99 | 7.99 | 14.99 | 27.97 | 35.89 |
| OPM % | 12.0% | 20.0% | 18.0% | 17.0% | 22.0% | 22.9% |
| Other Income | 1.01 | 1.01 | 2.01 | 8.02 | 10.03 | 7.83 |
| Interest | 0.00 | 0.00 | 1.01 | 4.01 | 5.01 | 4.84 |
| Depreciation | 0.00 | 0.00 | 0.99 | 4.99 | 5.99 | 6.83 |
| Profit before tax | 3.01 | 7.02 | 9.02 | 14.04 | 27.07 | 32.15 |
| Tax % | −32.0% | 8.0% | 32.0% | 23.1% | 29.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 3.99 | 5.98 | 5.98 | 9.96 | 18.93 | 23.03 |
| EPS (Rs) | 4.95 | 5.25 | 5.52 | 10.24 | 16.00 | 19.02 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 7.99 | 12.01 | 11.99 | 11.98 | 11.99 |
| Reserves | −3.00 | 33.90 | 40.89 | 52.83 | 87.74 |
| Borrowings | 2.00 | 8.01 | 17.98 | 53.92 | 72.93 |
| Other Liabilities | 6.97 | 8.95 | 15.93 | 36.83 | 61.71 |
| Total Liabilities | 13.96 | 62.87 | 86.79 | 156 | 235 |
| Fixed Assets | 0.99 | 2.99 | 20.95 | 43.90 | 60.81 |
| CWIP | 0.00 | 5.01 | 4.01 | 2.01 | 18.03 |
| Investments | 0.00 | 2.99 | 3.98 | 10.97 | 7.98 |
| Other Assets | 11.97 | 50.88 | 57.85 | 98.68 | 149 |
| Inventories | 3.99 | 6.98 | 12.96 | 27.92 | 35.90 |
| Trade receivables | 5.01 | 12.03 | 13.05 | 28.09 | 74.24 |
| Cash & equivalents | 0.00 | 13.96 | 6.98 | 1.99 | 3.99 |
| Total Assets | 13.96 | 62.87 | 86.79 | 156 | 235 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | −19.08 | 2.01 | −4.02 | 5.02 |
| Cash from investing activity | 0.00 | −10.02 | −20.01 | −14.02 | −37.04 |
| Cash from financing activity | 0.99 | 41.98 | 10.99 | 14.01 | 33.97 |
| Net cash flow | 0.00 | 13.99 | −6.99 | −4.01 | 1.99 |
| Capex | 0.47 | 6.94 | 17.94 | 11.13 | 36.57 |
| Free cash flow | −0.99 | −25.89 | −15.93 | −14.93 | −28.90 |
| CFO / OP % | −7.9% | −293.9% | 56.1% | 4.0% | 43.1% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 83 | 139 | 110 | 116 | 209 |
| Inventory days | 95 | 129 | 156 | 226 | 173 |
| Days payable | 133 | 86 | 93 | 118 | 181 |
| Cash conversion cycle | 44 | 182 | 173 | 224 | 199 |
| Working capital days | 48 | 274 | 204 | 143 | 133 |
| ROCE % | — | 23.0% | 15.0% | 18.0% | 21.0% |
For the Sep 2026 quarter, Trident Lifeline reported sales of ₹47.19 Cr, up 50.4% year on year and net profit of ₹6.58 Cr, up 29.5% year on year. The operating margin was 24.1%.
Trident Lifeline's sales for the year to Mar 2026 were ₹129 Cr; over the last twelve months they were ₹157 Cr.
Net profit for the year to Mar 2026 was ₹18.93 Cr, and ₹23.03 Cr over the last twelve months. Earnings per share over the same trailing period were ₹19.02.
Trident Lifeline reported borrowings of ₹72.93 Cr at Mar 2026, against cash and equivalents of ₹3.99 Cr.
Cash from operations was ₹5.02 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹28.90 Cr.